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MATERIALS OF INTERNATIONAL SCIENTIFIC CONFERENCE  
“INTEGRATED CLINICAL AND PATHOGENETIC APPROACHES 
IN DIAGNOSIS AND THERAPY OF CANCER”,  
JUNE 13–15, 2016, KYIV, UKRAINE
The International scientific conference “Integrated 
clinical and pathogenetic approaches in diagnosis 
and therapy of cancer” was held on June 13–15, 
2016 at R.E. Kavetsky Institute of Experimental Patho­
logy, Oncology and Radiobiology (IEPOR) of the Na­
tional Academy of Sciences of Ukraine, Kyiv, Ukraine.
The focus of the conference was a search for 
the new fundamental, translational and clinical ap­
proaches in cancer research, prevention, diagnosis 
and treatment. 
At the conference we have learned a lot of new 
data presented by researchers from many countries, 
namely Ukraine, Sweden, Latvia, Lithuania, Poland, 
and Belarus. 
The Director of IEPOR, Academician Vasyl Chekhun 
gave an overview on the research that was and is per­
formed at IEPOR, and also the future directions im­
portant to combat the cancer diseases. He discussed 
the concept of cancer stem cells, the importance 
of the multimeric interactions between cancer cells 
and normal cells, and microenvironment. Academi­
cian V. Chekhun highlighted that the research on stem 
cells were initiated at our Institute about half century 
ago by Academicians R. Kavetsky and Z. Butenko. 
And the First International Conference “Role of stem 
cell in leukemo­ and carcinogenesis” summarizing 
the early developments in the field was held at our 
Institute at that time.
The new level of the cancer problem was presented 
by Professor Ingemar Ernberg from Karolinska Insti­
tutet (Sweden) who presented his recent concept 
of cancer cell “attractor”, at the edge of tumor bio logy, 
mathematical modeling and system biology.
The keynote reports were presented also by Profes­
sor Ninel Berezhna, Doctor of Medical Sciences Victor 
Zhylchuk, Doctor of Sciences Iryna Kozeretska, Doctor 
of Sciences Olena Kashuba and Doctor of Sciences 
Denys Kolybo. The lecturers presented the up­to­date 
information on the role of connective tissue as the 
key factor of tumor microenvironment, the metastatic 
bone lesions and disseminated cancer cells in bone 
marrow, genetic aspects of cancer in Ukraine, the 
role of MRPS18­2 oncoprotein in regulation of cell 
differentiation, HB­EGF as potential oncomarker and 
target for anticancer therapy.
We have listen to many interesting reports, con­
cerning the choice of the targets for cancer therapy, 
presented by Ukrainian researchers (see enclosed 
abstracts). Cancer therapy and the problems of per­
sonalized cancer treatment were also in the spotlight.
During conference, largely supported by the 
VACTRAIN of Horizon 2020 program, there were work­
shops with the training in wet lab on different modern 
research techniques, such as quantitative real­time 
PCR (qRT­PCR), Comet assay, Fluorescence activated 
cell sorting (FACS), and also immunohistochemistry. 
Many Master and PhD students and also young and 
experienced researchers took part in the workshops. 
This conference was also a platform to popula­
rize the European School of Oncology, represented 
by Dr. Wojciech Wysocki from Poland. We are sure that 
this information will increase mobility of our medical 
students.
During conference, we had a great opportunity 
to show our beloved country as it is to our guests. 
There were excursions around Kyiv and a boat trip 
on Dnipro, the travel to the regional center Chernihiv, 
the ancient city north from Kyiv.
We hope that all participants got a take­home mes­
sage: we have a long and difficult way to go to cure 
cancer disease, and we hope we reach our goal in our 
life time.
PROGNOSTIC AND PREDICTIVE VALUE 
OF IODINE SYMPORTER IN HUMAN BREAST 
CANCER CELLS
A.V. Adriiv1,2, A.V. Lagutin2, V.F. Chekhun1
1R.E. Kavetsky Institute of Experimental  
Patho logy, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine  
2Ivano-Frankivsk Regional Clinical Oncology Center, 
Ivano-Frankivsk, Ukraine
Breast cancer (BC) is one of the most serious 
problems due to the high incidence and increasing 
number of patients with tumors resistant to chemo­
therapy. In this respect, the metabolic iodine  may have 
increasing relevance. In particular, there is an opinion, 
that iodine symporter can serve as a potential marker 
of tumor progression. We aimed to investigate the rela­
tionship between iodine symporter expression clinical 
and pathological characteristics of BC patients, and 
also to clarify its role in the determination of sensiti­
vity to cytostatics. The 162 BC patients at stage II–III, 
undergoing hospital treatment in the Ivano­Frankivsk 
Regional Clinical Oncology Center during 2013–2015, 
were studied. All patients received neoadjuvant 
chemotherapy (NAHT), a course which included 
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a 2–6 scheme cycles FAC, AC intervals of 21 days. 
Efficiency of NAHT was evaluated after every 2 cycles, 
according to mammography and ultrasound diagnostic 
criteria. The largest number of tumors showing expres­
sion of iodine symporter was in the stage III patients 
(73.4%), low degree of differentiation (60.4%), and 
in three negative (basal) molecular subtype tumors 
(68.2%). There was a correlation between iodine 
symporter expression and a stage of disease (r = 0.46; 
p < 0.05); the presence of metastatic lesion in regional 
lymph nodes (r = 0.49; p < 0.05), the degree of dif­
ferentiation (r = −0.42, p < 0.05), the basal molecular 
subtype (r = 0.44; p < 0.05), and tumor tissue sensiti­
vity to NAHT (FAC, AC) (p < 0.05). Conclusions: High 
levels of iodine symporter in tumors indicate resistance 
to NAHT and may be used as an additional prognostic 
and predictive marker of BC.
HEPATITIS C VIRUS POSITIVE 
HEPATOCELLULAR CARCINOMA 
RECURRENCE FREE SURVIVAL 
AND THE UCKL-1 AND S18-2 EXPRESSION
A. Buivydiene1, S. Jokubauskiene2, 
J. Norkuniene3, V. Liakina1, L. Jancoriene4, 
J. Valantinas5, E. Kashuba6
1Vilnius University, Clinic of Gastroenterology, 
Nephrourology and Surgery, Vilnius, Lithuania  
2Vilnius University, Department of Pathology, Forensic 
Medicine and Pharmacology, Vilnius, Lithuania  
3Department of Mathematical Statistics of Vilnius 
Gediminas Technical University, Vilnius, Lithuania 
4Vilnius University, Department of Infectious, Chest 
Diseases, Dermatovenerology and Alergology,  
Vilnius, Lithuania 
5Vilnius University Hospital Santariškių Klinikos, 
Centre of Hepatology, Gastroenterology and 
Dietetics, Vilnius, Lithuania 
6R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine,  
Kyiv, Ukraine
Despite recent advances in hepatocellular car­
cinoma (HCC) diagnosis and achievements in the 
treatment, a high risk of recurrence remains the 
Achilles heel of HCC care. Therefore, there is a need 
in reliable prognostic markers for proper follow 
up of patients with HCC. The uridine­cytidine kinase­
like protein 1 (UCKL­1) involved in cellular nucleotide 
metabolism and mitochondrial ribosomal protein 
S18­2 as intracellular signaling regulator can be con­
sidered as putative candidates because of their im­
portance in the tumor cells (including hepatocytes) 
transformation process. UCKL­1 and S18­2 expres­
sion has not been investiga ted yet in liver tissue 
and in HCC lesions. In presented study we explored 
UCKL­1 and S18­2 proteins value as hepatitis 
C virus (HCV) positive HCC relapse risk prognostic 
markers. 42 liver biopsies of HCV patients with suc­
cessfully treated HCC were analyzed. HAI, fibrosis 
score, HCC differentiation and vascular invasion 
have been evaluated in every biopsy. Oncoproteins 
expression was visualized by immunohistochemistry 
staining with polyclonal rabbit anti­UCKL­1 and anti­
S18­2 antibodies, using EnVision G2 double staining 
system. The average of expression was calculated 
by multiplying the frequency of stained cells and 
sta ining intensity. HCC recurrence in HCV cirrhosis 
was radiologically confirmed in 27 of the 42 patients. 
All patients were followed up from 1 to 8 years; HCC 
relapse appeared after 1–5 years. In relapses morta­
lity rate was significantly higher than in the absence 
of HCC relapse: 59.3% vs 6.7%, respectively; p = 
0.001. HCC relapse occurred more often in older 
patients (63.78 ± 9.22 vs 53.53 ± 4.07; p < 0.001). 
Patients gender, body mass, HAI and fibrosis score 
as well as portal hypertension signs, biochemical 
indices of liver damage, HCV genotype, and viral load 
did not influence HCC recurrence. In relapses HCC 
nodules were larger (50.44 ± 17.83 mm vs 41.47 ± 
20.76; p = 0.148), vascular invasion was more com­
mon (p = 0.02), but HCC differentiation had no predic­
tive value for recurrence. In relapses UCKL­1 staining 
was observed significantly more enhanced in the 
HCC nodules than in absence of recurrence (62.69 ± 
50.4 vs 26.0 ± 30.19; p = 0.006). There were no diffe­
rence in UCKL­1 staining in the unaffected liver tissue 
between relapsers and non­relapsers. Regardless 
of HCC relapse (p = 0.378) S18­2 staining was several 
times greater in the HCC nodules than in unaffected 
liver. HCC treatment method itself has also significant 
predictive value — in case of liver transplantation 
the recurrence rate was appreciably lower than after 
liver rejection or RFTT (p = 0.001). Conclusions: 
It is likely that strong UCKL­1 signal in HCC nodules 
indicates the higher risk of HCC relapse after initial 
successful treatment, especially if it was not a liver 
transplantation. S18­2 signal is higher in the HCC 
nodules, than in the unaffected liver; however, it has 
no prognostic value. 
ADVANCED LIVER RESECTION AND TUMOR 
PROGRESSION
A.A. Burlaka, A.B. Lukashenko, O.O. Kolesnik
National Cancer Institute, Kyiv, Ukraine
Despite the introduction into clinical practice 
a study on the functional reserve of the liver, calculating 
the volume of future residual stump of the liver, as well 
as the use of portal vein embolization or an associ­
ated division of liver and portal vein ligation — severe 
hepatic insufficiency (SHI) is the main cause of com­
plications and mortality of patients. We aimed to find 
the new approaches to prevent SHI and to control 
SHI in the postoperative period. The developed scale 
and principles of SHI diagnosis described in (Nuh N. 
Rahbari et al., 2015) will be used in the future studies 
to standardize surgical complications in the postopera­
tive period. The study of physiological changes in the 
tissues of the operated liver of cancer patients will 
improve diagnosis and control on SHI.
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A REDOX STATE OF FATTY TISSUE 
IS A CRITICAL FACTOR IN THE 
PROGRESSION OF GASTROINTESTINAL 
TRACT TUMORS
A.P. Burlaka1, I.I. Ganusevich1, A.V. Vovk1, 
L.D. Gumenjuk1, V.V. Golotyuk2, S.M. Lukin1 
1R.E. Kavetsky Institute of Experimental  
Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine  
2Ivano-Frankivsk National Medical University,  
Ivano-Frankivsk, Ukraine
Studies on the involvement of mitochondria 
in metabolic changes in fat tissues (FT) adjacent 
to is important in understanding of the complex 
relationship between tumor and adipose tissue (AT) 
that contribute to the progression of cancer. Hyper­
trophied and dysfunctional AT at obesity is charac­
terized by activation of the generation of superoxide 
radicals (SR), which is manifested by inflammation. 
We aimed to investigate the redox state of tumor 
adjacent AT and its relationship with metastasis 
of stomach (SC) and colorectal (CC) cancers. 
11 samples of healthy individuals, 29 SC samples, 
and 27 CC samples of the patients at stages II–III 
(T2–4N0–2M0G2–3) were studied, using EPR (in the 
liquid nitrogen) and Technology Spin Traps, and also 
by immunohistochemistry, and statistics. We have 
found that the level of acti vity of the electron trans­
port chain complex in mitochondria in AT adjacent 
to tumors correlated with the degree of differentiation 
of CC and SC (r = 0.64, r = 0.47; p < 0.05). Moreover, 
SR generation and and oxidation­induced DNA muta­
tions is 3.5 folds higher, when compared to healthy 
individuals (p < 0.05). The high levels of SR genera­
tion in AT adjacent to tumors is associated with a high 
number of tumor­associated adipocytes, macro­
phages in tumor tissue, and with distant metastasiz­
ing (p < 0.05). Conclusions: Defects in the oxidative 
phosphorylation mechanisms, a high rate of SR gen­
eration, the increasing rate of guanine oxidation and 
activity of matrix metalloproteinases in AT adjacent 
to tumors are important factors in tumor progression. 
These indicators may have the prognostic value for 
SC and CC patients.
PROGNOSTIC SIGNIFICANCE 
OF EXPRESSION OF TUMOR SUPPRESSOR 
microRNA 122, 133a, AND 200b IN BREAST 
CANCER PATIENTS
V.F. Chekhun, T.V. Borikun, T.N. Yalovenko, 
N.Yu. Lukianova
R.E. Kavetsky Institute of Experimental  
Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine
In recent years it is evidenced the usefulness of the 
new epigenetic markers, especially miRNAs for prog­
nosis of a course of cancer disease. It was shown that 
the development of tumors of various origins, including 
breast cancer (BC) is accompanied by a reduction 
in tumor suppressor miRNAs targeting oncogenes 
which are involved in regulation of cell division, inva­
sion, apoptosis, proliferation, and metastasizing. 
We wanted to determine the relationship between 
expression of miR­122, ­133a and ­200b in tumor cells 
and the clinico­pathological parameters of BC to as­
sess their prognostic significance. The study involved 
145 patients with BC at the stage I–III. Expression 
of miR­122, ­133a, and ­200b in tumor cells was 
determined by the real time RT­PCR. As a control, 
14 samples of visually intact breast tissue were used. 
We have found that expression of miR­122, ­133a, and 
­200b was diminished 5.2 ± 0.67, 2.8 ± 0.34, and 4.1 ± 
0.29 folds, respectively, in BC samples in comparison 
with normal breast tissue. There is a correlation be­
tween expression levels of all of the studied miRNAs 
and the basic clinical and pathological characteristics 
of BC. In particular, we found the inverse correla­
tion of miR­200b, ­133, and ­122 with the presence 
of regional metastases in lymph nodes (r = −0.46, 
r = −0.38, r = −0.4, respectively; p < 0.05). The lowest 
levels of miR­122 (0.040 ± 0.006 relative units) and 
miR­200b (0.050 ± 0.007 relative units) were detected 
in the cells of the triple­negative (ER−, PR−, HER2−) 
BC, compared with other molecular subtypes. Also 
we have found that the reduced expression of miR­
133a (<3 relative units) in tumor tissue is associ­
ated with the high risk of recurrence of BC (r = 0.49). 
Conclusions: The correlation of expression of tumor 
suppressor miR­122, ­133a, and ­200b with clinical 
and pathological characteristics of BC, such as me­
tastases, basal molecular subtype and the disease­
free survival make it possible to use these microRNAs 
as the additional prognostic markers of BC progress.
CHANGES IN SYSTEM OF CELL REGULATING 
REDOX- AND GLYCOLYTIC FACTORS 
IN WALKER-256 CARCINOSARCOMA 
TISSUES WITH DIFFERENT SENSITIVITY 
TO DOXORUBICIN
V. F. Chekhun, Yu.V. Lozovskaya, N.Yu. Lukianova, 
I.M. Todor, I.I. Ganusevich, A.P. Burlaka
R.E. Kavetsky Institute of Experimental  
Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine
Zn­dependent matrix metal loproteinases 
(MMP)­2 and ­9 play an important role in tumor pro­
gression, especially in the invasion, metastasizing and 
angiogenesis. We wanted to investigate the relation­
ship between glycolytic and redox indicators, i.e. the 
number of “free iron” (FI), the generation of superoxide 
radical anion (SRA), the ratio of Cu/Zn, and levels 
of lactate dehydrogenase (LDH), ferritin (FR), and 
also the MMP­2 and ­9 activity in tumor tissue (TT) 
of animals with different sensitivity to doxorubicin. 
Studies were conducted in vivo on two groups of ani­
mals with carcinosarcoma Walker­256, original and 
with induced resistance to doxorubicin. In two groups 
of animals we have found the oppositely directed changes 
in glycolytic and redox indicators. In sensitive to doxo­
rubicin animals there were increased levels of FI and 
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Cu/Zn 1.2 fold, SRA — 3.1 fold, LDH — 1.4 fold. Other 
direction of changes was observed in resistant to doxoru­
bicin animals: decrease of FI 1.6 fold, Cu/Zn and SRA — 
1.2 fold, LDH — 1.3 fold. Regardless of the sensitivity 
of cells to doxorubicin, the higher levels of FR were 
detected in carcinosarcomas. Parallel to that we have 
observed multidirectional changes in the activity 
of MMP­2 and ­9. In TT, sensitive to doxorubicin their 
activity increased 1.4 and 1.2 fold, respectively, while 
in the resistant TT the 1.4 and 1.6 fold decrease was 
detected. Conclusions: Changes in glycolytic and 
redox indicators, the ratio of Cu/Zn, detected after 
doxorubicin treatment in tumor tissues with different 
sensitivity to it, are associated with activation or inhibi­
tion of MMP­2 and ­9. This may be used to correct the 
metastatic and angiogenic activity of the transformed 
cells to increase their sensitivity to the action of anti­
cancer drugs.
CYTOTOXIC EFFECTS OF EXOGENOUS 
LACTOFERRIN ON BREAST CANCER CELLS 
WITH DIFFERENT DEGREE OF MALIGNANCY 
IN VITRO
V.F. Chekhun1, D.M. Storchay1, Y.V. Shvets1, 
N.Yu. Lukianova1, V.S. Lukashevych2, 
I.V. Semak3, H.E. Zalutskyy2
1R.E. Kavetsky Institute of Experimental  
Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine  
2Institute of Physiology, NAS of Belarus,  
Minsk, Belarus  
3Belarusian State University, Minsk, Belarus
Experimental studies have shown that the highest 
activity as antioxidants, compared with synthetic ana­
logs, has a natural antioxidant protein lactoferrin (LF). 
We wanted to investigate the impact of exogenous 
LF on breast cancer cell lines of different degrees 
of malignancy in vitro. To do so, we have chosen 
cells with a low (MCF­7, T47D) and the high degree 
of malignancy (MDA­MB­468, MDA­MB­231). LF was 
added in a dose at the IC30 (100 mg/ml) for 48 h. It was 
observed that LF induced apoptosis. The cells of the 
high degree of malignancy, MDA­MB­468 and MDA­
MB­231 showed the highest number of the dead cells 
(43.2 ± 2.5 and 41.4 ± 2.1%, respectively). This was 
accompanied by downregulation of Bcl­2 by 19.5%, 
and increased expression of pro­apoptotic protein Bax 
by 13.5%. The DNA in comet tail for MDA­MB­468 and 
MDA­MB­231 cells showed a significant increase 
too, at 3.9 ± 0.5 and 3.8 ± 1.2% fold, respectively 
(p < 0.05). The observed cytotoxic effects of LF were 
accompanied by the cell cycle arrest in G2/M phase. 
Conclusions: The peculiarities of cytotoxic and geno­
toxic action of exogenous LF indicate possibility to use 
it to modify the phenotype of breast cancer cells of the 
high degree of malignancy.
PATTERN OF EXPRESSION OF CANCER 
STEM CELLS MARKERS, СD44 AND CD24, 
IN MALIGNANT PROSTATE TUMORS 
V.F. Chekhun1, T.V. Zadvornyi1, Yu.V. Zhylchuk2, 
N.Yu. Lukianova1, R.A. Lytvynenko3, 
Yu.V. Vitruk3, M.V. Pikul3, A.E. Stakhovsky3, 
E.A. Stakhovsky3
1R.E. Kavetsky Institute of Experimental  
Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine  
2Institute of Urology, NAMS of Ukraine, Kyiv, Ukraine 
3National Cancer Institute, Kyiv, Ukraine
In recent years, there is growing body of evidences 
that a distinct subpopulation of tumor cells, i.e. can­
cer stem cells (CSC, cancer initiating cells) exists. 
The presence of these cells is a determining factor for 
the growth and progression of tumors, their metastatic 
activity, and sensitivity to chemo­ and radiotherapy. 
We aimed to investigate the expression pattern of the 
CSC markers, such as CD44 and CD24 in prostate 
malignant tumors and find a relationship between 
their expression and pathological characteristics 
of patients. The study involved 86 patients with pros­
tate cancer at the stages II–III. The presence of the 
CD24 and CD44 antigens in tumor tissue section was 
found in 52.3 and 75.6% of the total number of tumor 
samples, respectively. Number of tumors that showed 
expression pattern as CD44+/CD24−/low in CSC was 
32.5%. The largest number of CD44+ and CD44+/
CD24−/low tumors was identified in patients at the 
stage III (77 and 53%, respectively) compared with 
patients with prostate cancer of the stage II (65 and 
28%, respectively). We also found that high levels 
of prostate specific antigen (PSA, > 15 ng/ml) that 
was detected in the serum of prostate cancer patients 
was associated with increased number of CD44+ and 
CD44+/CD24−/low cells. We have found that patients 
with a CSC phenotype as CD24− and CD44+/CD24−/low 
showed a higher (3.0 and 3.3 fold) incidence of relapse 
compared with patients with other tumor cell pheno­
type. Conclusions: We found a correlation between 
patterns of CD24 and CD44 expression and clinical and 
pathological features of prostate cancer. This suggests 
that expression of CSC markers may be used as ad­
ditional criteria for prognosis of the course of disease.
CLINICAL SIGNIFICANCE OF THE ISOLATED 
TUMOR CELL DETECTION 
IN THE PERITONEAL LAVAGE SOLUTION 
IN PATIENTS WITH RESECTABLE 
PANCREATIC DUCTAL ADENOCARCINOMA
O.I. Dronov, S.V. Zemskov, D.I. Khomenko
O.O. Bogomolets National Medical University, Kyiv, 
Ukraine
Clinical role of the isolated tumor cells (ITC) in peri­
toneal lavage solution of pancreatic cancer (PC) pa­
tients is disputable. The aim of this study was to evalu­
ate the influence of ITC in peritoneal lavage of PC pa­
tients after curative resection on overall survival (OS) 
recurrence free survival (RFS) and investigate the role 
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of surgery in peritoneal dissemination of PC. 22 re­
sected patients with PC were consequently involved 
into the study. PC was proved histologically in all cases. 
All patients underwent adjuvant chemotherapy. Me­
dian age was 63 (45–74) years. Peritoneal lavage was 
aspirated from 3 areas intraoperatively. Aspiration was 
performed at laparotomy and at the end of surgery. 
Paraffin blocks were made of the aspirates sediment. 
Cytological samples were investigated histologically 
and immunocytochemically (ICC). CEA monoclonal 
antibodies (MAB) (clone II­1, DAKO, Danmark) and 
CA 19­9 MAB assays (clone C241:5:1:4, Diagnostic 
Biosystems, USA) were applied. ITCs were registered 
in none of 22 patients at laparotomy. In 2 patients ITCs 
were identified by ICC. No influence on patient prog­
nosis was seen when analyzing OS and RFS. Median 
RFS was 12 months. Conclusions: At present, ICC 
method and cytological examination can’t be used 
as an adequate tool in evaluation of intraoperative 
peritoneal dissemination of PC or in prognosis of re­
sectable patients with PC. 
WHAT IS THE MOST EFFICIENT 
IMMUNOTHERAPY TO EPSTEIN — BARR 
VIRUS (EBV) INFECTION?
I. Ernberg
Department of Microbiology, Tumor and Cell Biology 
(MTC), Karolinska Institutet, Stockholm, Sweden
Epstein — Barr virus (EBV) is the most common 
pathogenic virus in the human population with a preva­
lence globally > 90%. As a herpesvirus it remains 
latent after primary infection throughout life. Every 
year EBV is involved in the pathogenesis of some 
200,000 new cancers, affecting the immune system, 
nasopharynx or stomach. The viral carcinogenesis 
depends on cofactors such as genetic, co­infection 
or immunologic (e.g. immunosuppression). In healthy 
people primary infection often results in infectious 
mononucleosis (IM), a self­limiting lymphoproliferative 
disease, particularly if it is delayed to adolescence. 
We study EBV­related complications and cancers 
in HIV­infected patients, transplant patients and in the 
Chinese population with high risk of nasopharyngeal 
cancer (NPC; 1–5). In this lecture the most appropriate 
type of immunotherapy against EBV­infection and its 
complications will be discussed. Restoration of host 
cellular immunity and/or adoptive T­cell therapy has 
been successfully employed to block post­transplant 
lymphoproliferative disease (PTLD) and lymphomas 
in immunosuppressed patients (3–5). NPC is usually 
treated with radio­ and chemotherapy. In the future 
NPC should be subject to immunotherapy trying 
checkpoint inhibitors. Conclusions: There is an effi­
cient vaccine to EBV directed against its main receptor 
ligand gp 350. However it is hard to define a target 
population for cost­effective preventive vaccination, 
given the wide dissemination of the virus, the nature 
of primary infection and of the host­virus interaction. 
On the other hand, immune based therapies will not 
likely gain increased attention.
THE GENETIC DETERMINANT 
OF ENDOMETRIAL CANCER SUSCEPTIBILITY
N.M. Glushchenko, I.P. Nesina, L.G. Buchynska
R.E. Kavetsky Institute of Experimental  
Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine
Earlier, we have identified differences in the con­
tribution of genetic factors to cancer of the female 
reproductive system (FRS): genetic component in the 
development of endometrial cancer (EC) is 61.0%, 
breast — 56.0%, ovary — 67.0%, and cervix — 3.0%. 
However, the specific clinical indicators relative to their 
importance for the emergence of tumors of vari­
ous origins, including EC, has not been evaluated. 
We aimed to determine the most informative indica­
tors associated with the occurrence of EC. The clinical 
and genealogical analysis of 218 patients with EC was 
performed. The special software packages of genetics 
and mathematical analysis were used. By the analysis 
of the pedigrees of patients with EC we have found that 
in the families of 144 (65.5%) patients no aggrega­
tion of cancer pathology was observed. Noteworthy, 
for 77 (34.5%) patients the FRS, colon, stomach, 
and malignant neoplasms of other origin were found 
among relatives of the first and the second degrees. 
In EC patients with aggregation of FRS in genealogy, 
the informative significance were attributed to: age 
of occurrence of cancer before 45 years (I = 0.50) and 
in the ages of 55–65 years (I = 0.50); clinical parame­
ters, such as the number of abortions — more than 
4 (I = 0.75), and late onset of menarche — 15 years 
and over (I = 0.58). It should be noted that in patients 
with EC with a family history of cancer there is hidden 
chromosomal instability (inductor bleomycin), infor­
mativity of which was 0.86. Conclusions: our research 
revealed a set of the most informative features that 
determine the risk for the occurrence of EC.
EXPRESSION OF CD150 ISOFORMS 
IN NORMAL AND MALIGNANT B CELLS 
AT THE DIFFERENT STAGE OF MATURATION
I.M. Gordiienko, L.M. Shlapatska, 
L.M. Kovalevska, S.P. Sidorenko
R.E. Kavetsky Institute of Experimental  
Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine
CD150 (IPO3/SLAMF1) is mult ifunctional 
type I transmembrane glycoprotein that belongs 
to SLAM family within the immunoglobulin superfamily 
of surface receptors. Within B­cell lineage cell surface 
receptor CD150/SLAMF1 is broadly expressed  starting 
from pre­B cells with upregulation toward plasma 
cells. However, expression of CD150 is rather limited 
on the surface of malignant B cells with the block 
of differentiation at the different stages of maturation. 
The existence of alternatively spliced CD150 isoforms 
with different signaling properties indicates that 
they may mediate multiple functions by differential 
expression in lymphoid population at different stage 
of cell maturation. The aim of our work was to explore 
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CD150 expression both on protein and mRNA levels 
with the emphasis on CD150 isoforms in malignant 
 B­cell lines at the different stages of maturation 
in comparison with their normal B cell counterparts. 
Protein CD150 expression was accessed by western 
blot analysis and the expression level of CD150 iso­
forms was evaluated using qRT­PCR.
Despite the similar CD150 expression levels both, 
at the mRNA and protein levels in normal B­cell 
subsets and B­lymphoblastoid cell lines, malignant 
B­cell lines demonstrated substantial heterogeneity 
in CD150 expression. The CD150 protein was detected 
only in Hodgkin’s lymphoma cells, Burkitt’s lymphoma 
cell lines BJAB and Raji, and also pre­B cell line BLIN­1. 
At the same time, total CD150 and mCD150 mRNA was 
detected in all studied cell lines, except pre­B cell 
line REH. The minor sCD150 isoform was found only 
in Hodgkin’s lymphoma cell lines and Burkitt’s lym­
phoma cell line Raji. The nCD150 mRNA was revealed 
in all tested cell lines with the exception of pre­B ALL 
cell line REH and BL cell line Daudi. Similarly to normal 
B­cell subsets, in malignant B­cell lines expression 
level of nCD150 was tenfold lower, compared to the ex­
pression of mCD150 isoform. Conclusions: Malignant 
B­cell lines at the different stages of maturation re­
semble their normal counterparts partially,  concerning 
CD150 expression pattern. CD150 isoforms are diffe­
rentially expressed in normal and malignant B cells with 
predominant expression of mCD150 isoform.
BODY MASS INDEX AND TUMOR-
ASSOCIATED MACROPHAGES IN PATIENTS 
WITH GASTRIC CANCER: ASSOCIATION WITH 
THE COURSE OF DISEASE 
L.D. Gumenyuk, I.I. Ganusevich
R.E. Kavetsky Institute of Experimental  
Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine
Obesity increases the risk of cancers and worsens 
the disease. Infiltration by macrophages is a common 
feature in inflammation and obesity. It is shown that 
adipose tissue that surrounds the tumor or metastases 
in the lymph nodes serves as the energy source for 
tumor growth and depots macrophage, stimulating 
angiogenesis and the pro­tumor functions as tumor­
associated macrophages (TAM). We aimed to deter­
mine the relationship between body mass index (BMI), 
number of TAM and overall survival (OS) of patients with 
gastric cancer (GC). The 128 GC were studied, grouped 
by BMI (< 25 kg/m2 — normal body weight, ≥ 25 kg/
m2 — overweight and obesity). Immunohistochemistry 
was used  to determine TAM (CD68+ cells). Patients 
with a BMI ≥ 25 kg/m2, regardless of age, showed 
a significant greater number of TAM than people of nor­
mal weight. In patients aged < 60 years, TAM positive 
correlation with BMI is more pronounced (r = 0.4, p < 
0.05). Patients whose tumors are chara cterized by a lot 
of TAMs have lower life expectancy and the higher risk 
of adverse disease, than patients with low TAM (log­
rank test: p < 0.01, HR = 2.5). Conclusions: In patients 
with GC overweight and obesity there is more intense 
infiltration of TAM in tumor tissue than in patients with 
normal weight. Number of TAMs is associated with BMI 
patients and can be used for prognosis of GC.
ADAPTOR PROTEIN Ruk/CIN85  
PROMOTES LUNG METASTASIS 
OF 4T1 MURINE BREAST 
ADENOCARCINOMA CELLS
I. Horak, D. Shytikov, D. Petukhov, 
G. Pasichnyk, L. Drobot
O.V. Palladin Institute of Biochemistry, 
NAS of Ukraine, Kyiv, Ukraine
Adaptor proteins consist of several binding domains 
and motives and usually do not have any catalytic ac­
tivities. Through interaction with their binding partners, 
adaptors play crucial role in organization, structuring 
and regulation of multimolecular complexes, involved 
in the control of cell responses. Adaptor protein Ruk/
CIN85 is involved in motility, invasion, and adhesion 
of murine 4T1 breast adenocarcinoma cells. The aim 
of present study was to investigate the effect of Ruk/
CIN85 on 4T1 cells metastasis in vivo.  In order to ex­
plore Ruk/CIN85 impact on metastasis, we generated 
4T1 sublines with stable Ruk/CIN85 overexpression. 
5•105 cells were injected into the tail vein of 8 weeks old 
Balb/c female mice. After 24 h the mice were sacrificed 
and lungs were excised. Amount of migrated cells was 
evaluated with lung seeding assay, and lung perme­
ability assay was performed using Evans blue dye. For 
experimental metastasis assay we injected 5•105 cells 
into the tail vein and after 14 days collected lungs for 
metastasis assessment. Statistical analysis was per­
formed, using Mann — Whitney U­test. We have found 
that the mice injected with Ruk/CIN85­overexpressing 
4T1 cells are characterized by increased amount 
of cells, which invaded into lungs, and higher lung ves­
sels endothelium permeability in comparison to control 
mice. Experimental metastasis assay showed higher 
number of lung metastasis as well as lung to body mass 
ratio in group injected with Ruk/CIN85­overexpressing 
cells when compared to control. Conclusions: Taken 
together, these data indicate higher metastatic poten­
tial of 4T1 cells with Ruk/CIN85 overexpression. 
THE STUDY OF THE NUMBER OF TUMOR-
INFILTRATING FOXP3 POSITIVE LYMPHOCYTES 
IN ENDOMETRIAL CARCINOMAS 
IN DEPENDENCE ON THE MISMATCH REPAIR 
STATUS IN PATIENTS WITH A FAMILY HISTORY 
OF CANCER
N.P. Iurchenko1, O.V. Bryeyeva1, 
O.O. Samohvalova2, L.G. Buchynska1
1R.E. Kavetsky Institute of Experimental  
Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine 
2National Cancer Institute, Kyiv, Ukraine
Endometrial cancer (EC) can occur in a patient 
from a family with the history of a number of hereditary 
cancer syndromes, the most common of them is Lynch 
syndrome. The Lynch syndrome is characterized 
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by germline mutations in mismatch DNA repair genes 
(MMR). It is known that disruption of MMR­system 
leads to a large number of immunogenic proteins, re­
sulting in a high lymphocytic infiltration in such tumors. 
We aimed to estimate the number of FOXP3+ intra­tumor 
lymphocytes in ECs in dependence on a status of MMR 
system in patients with a family history of cancer. The sur­
gical samples of 49 patients of the stage I–II of EC were 
studied. Patients did not receive any treatment before 
surgery. By the clinical and genealogical analysis 
of pedigrees of EC patients we found that 26.5% of pro­
bands had cancer family history. Most families have 
accumulated tumors of the female reproductive system 
and the gastrointestinal tract. We have shown that the 
number of EC patients with MMR­deficient tumors was 
significantly greater in patients with family cancer history 
(61.5%), compared with the group of patients without 
aggregation of cancers in families (27.8%). Microsat­
ellite instabi lity resulting from the disruption of MMR 
system was found in 10.7% of EC patients, including one 
patient with a family of aggregation Lynch­associated 
tumors. We have also found that in EC patients with the 
fami ly history the high number of FOXP3+ lymphocytes 
were detected in 40% of MMR­deficient tumors; while 
among cancers with normal MMR infiltration of FOXP3+ 
lymphocytes was significantly higher, up to 66.7%. Most 
MMR positive carcinomas with a high number of FOXP3+ 
intra­tumor lymphocytes were characterized by a low 
degree of differentiation and the deep tumor invasion into 
the myometrium. Conclusions: We have found that the 
infiltration of FOXP3+ lymphocytes in EC correlates with 
tumor MMR status in patients with a family history, and 
also is associated with tumor progression.
CLINICAL BENEFIT OF PERSONALISED 
DENDRITIC CELL BASED VACCINE THERAPY 
ACCORDING TO THE PD-L1  
TUMOR EXPRESSION IN PATIENTS 
WITH NON-SMALL CELL LUNG CANCER
N.M. Khranovska, O.V. Skachkova, R.I. Sydor, 
M.V. Inomistova, V.M. Sovenko, Y.N. Kondratsky
National Cancer Institute, Kyiv, Ukraine
Modern antitumor vaccination therapy is one of the 
most promising strategies in lung cancer biotherapy 
today. Earlier, promising results from phase III trial 
of dendritic cell based vaccine immunotherapy for 
the non­small cell lung cancer (NSCLC) patients 
at IIB–IIIA stages have been obtained by National 
Cancer Institute of Ukraine. It is known that the PD­1/
PD­L1 pathway plays an important role in blunting 
immune response to tumor vaccines. The predictive 
value of PD­L1 tumor expression is controversial. 
We speculate that DC­vaccine will have more benefit 
in NSCLC with low/− PD­L1 expression in tumors. 
Therefore, our main goal is to examine the clinical 
benefit of personalized DC­vaccine therapy in NSCLC 
patients, according to PD­L1 expression. The following 
original design of DC­vaccine was used: autologous 
DCs of monocytic origin were loaded with mechani­
cally heterogenized microparticles of tumor cells. 
Maturation state and functional activity of DCs were 
evaluated by the expression pattern of CD83/86, 
HLA­DR, and IL­12, and also the p35/p40 mRNA 
levels. The 4.62 ± 0.37•106 of DCs were injected 
intravenously in 1–3 courses with 6 months interval. 
One course consisted of 5 injections with one­month 
interval. Clinical and immunological monitoring was 
performed. The PD­L1 expression was detected 
in primary tumors by real­time RT­PCR. Tumors were 
categorized into groups, according to high or low PD­
L1 expression levels based on cutoff point (AUC = 0.79; 
p < 0.03). Sensitivity and specificity of PD­L1 gene 
expression as a predictive biomarker for NSCLC pa­
tients that received DC­vaccine therapy were 75 and 
83%, respectively. Cox proportional hazard regression 
analysis revealed that PD­L1 expression has no effect 
on the 5­year overall survival rate for NSCLC patients; 
it has a significant impact on 5­year event­free survival 
(EFS). The lower expression of PD­L1 correlates with 
a significant increase in EFS (p = 0.026). The 2­year 
EFS rate for patients with low PD­L1 expression was 
86% compared to 29% for high expression (F­Cox cri­
terion: F = 4.68; p = 0.017). Conclusions: Expression 
of PD­L1 in tumors has a predictive role for persona­
lized DC­vaccine therapy. Obtained results might serve 
as a background for the new therapy schemes, based 
on PD­1 inhibitors and/or specific immunotherapy.
PROTECTIVE ACTION OF QUERCETIN 
IN EXPERIMENTAL MODEL OF PULMONARY 
FIBROSIS: EFFECT ON ANTI-INFLAMMATORY 
POLARIZATION OF PHAGOCYTES 
IN ALVEOLAR LAVAGE
D.L. Kolesnik1, O.G. Fedorchuk1, 
A.S. Shalamaj2, V.G. Vedmid’2, G.I. Soljanik1
1R.E. Kavetsky Institute of Experimental  
Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine  
2PJSC SIC “Borshchahivskiy Chemical 
Pharmaceutical Plant”, Kyiv, Ukraine
It is known that toxic manifestations of anticancer 
chemotherapy limit significantly treatment outcomes 
of cancer patients and worsen their quality of life. One 
manifestation of side effects of anticancer drugs is the 
formation of fibrosis of lung and/or heart. One of the 
main causes and prerequisites of fibrosis is inflammation, 
when polarization of phagocytes is observed. One of the 
promising methods to prevent fibrosis is activation of the 
anti­inflammatory function of phagocytes by bio­flavo­
noids (characteri zed by a wide range of pharmacological 
activities, including antioxidant). We have investigated 
the ability of quercetin to stimulate polarization of in­
flammatory phagocytes in alveolar lavage of mice and 
adjust development of pulmonary fibrosis by bleomycin. 
The study was conducted on S57Vl/6 mice. 28 days 
after bleomycin administration the number of infiltrating 
the lungs phagocytic cells and their phagocytic activity 
and production of reactive oxygen species (ROS) were 
determined. The introduction of quercetin at doses 
of 0.45 and 4.5 g/kg resulted in reduction of infiltrating 
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and total number of lung phagocytes, compared to the 
control, up to 38.5% (p < 0.05) and 42.3% (p < 0.05), 
respectively. Integral phagocytic activity of immune cells 
in the lung lavage of mice upon quercetin treatment 
increased significantly, due to activation of neutrophils 
absorbance on 65.1 and 90.3%, respectively. Conclu-
sions: Quercetin shows the protective effect upon the 
formation of bleomycin­induced lung fibrosis, when 
administered at a dose of 4.5 g/kg. This is evidenced 
by a decrease in lung infiltration by phagocytic cells, 
their polarization towards the anti­inflammatory effects, 
and by reduced content of hydroxyproline in the lungs 
of experimental animals.
CYTOGENETIC MARKERS OF INITIATION 
AND PROGRESSION OF CANCEROGENESIS 
IN DIFFERENT STRAINS OF MICE 
O.M. Koval’ova, Yu.I. Kudryavets 
R.E. Kavetsky Institute of Experimental  
Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine
Multistage carcinogenesis is one of the main reasons 
why it is difficult to identify the key events. We wanted 
to expose a link between chromosomal instability and 
increased sensitivity for tumor promotion in laboratory 
mice and to identify the most informative cytogenetic 
characteristics, useful for assessing the stage of spon­
taneous and induced cancer. We stu died the mutational 
spectra in bone marrow (BM) cells of mice BALB/c, 
C57BL/6, DBA, and ICR at the control conditions and 
upon induction of tumors (melanoma B­16, breast 
adenocarcinoma Ca755, spontaneous carcinogenesis 
in ISR mice). We have found that in the control BM cells 
in young mice of high tumor incidence — BALB/c, DBA, 
and ICR — the cytogenetic instability was manifested 
long before tumor development. With age, ICR mice 
showed the increasing levels of aneuploidy in BM cells, 
and also the high number of cells with chromosomal ab­
errations, asynchronous splitting of centromeric regions 
of chromosomes, chromosome associations by type 
of Robertson translocations, the high frequency of lym­
phocytes with micronuclei, and also mitotic, apoptotic 
cells, nuclear abnormalities, pathological mitosis. Con-
clusions: Reduction of chromosomal stability is closely 
associated with tumor stage; the increased number 
of mitotic cells contributes to tumor progression.
INFLUENCE OF IFN-beta GENE 
TRANSDUCTION ON SENSITIVITY OF TUMOR 
CELLS TO CHEMOTHERAPY 
O.O. Lykhova1, N.O. Bezdenezhnykh1, 
K. Saulenko1, L. Strokovskaya2, Yu.I. Kudryavets1
1R.E. Kavetsky Institute of Experimental  
Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine  
2Institute of Molecular Biology and Genetics, 
NAS of Ukraine, Kyiv, Ukraine
One of the main treatments for cancer patients 
is the combined chemotherapy, which may include 
cytokines or the expression vectors, bearing genes, 
encoding cytokines. Also, it is important to determine 
the effectiveness of a drug combination to identify 
sy ner gistic or antagonistic nature of their interac­
tion. The aim of our work was to study the sensitivity 
of tumor cells that were transduced by a recombi­
nant baculovirus, bearing the IFN­beta (rBV/IFN) 
to the chemotherapy. Melanoma B16 cells (MM4) 
and Lewis lung carcinoma cells (LL) were chosen 
for transduction. We have found that transduction 
of MM4 cells by rBV/IFN and led to a significant 
increase in sensitivity of melanoma cells to dacarba­
zine (an anti­metabolite). Thus, IC50 of dacarbazine 
to control MM4 cells was 100 mg/ml, and for trans­
duced MM4 /rBV/IFN cells — only 10 mg/ml. Unlike 
melanoma cells, transduction of the LL cells by rBV/
IFN led to a significant increase in their sensitivi ty 
to cisplatin, docetaxel and etoposide. Thus, for the 
control cells IC50 of cisplatin was 0.5 mg/ml, and cells 
for transduced cells — 0.25 mg/ml; IC50 of docetaxel 
for the control cells amounted to 5 ng/ml, and for 
transduced cells — 1.5 ng/ml. Integrated action 
of etoposide on transduced LL/rBV/IFN increased also 
their sensitivity to the drug, two­folds. Conclusions: 
Our data suggest that the effectiveness of combina­
tion gene­ and chemotherapy can be personalized. 
It will depend largely on several conditions, including 
the tumor type, sensitivity of tumor cells to IFN and 
chemotherapy, the cell cycle phase after transduction, 
and also other factors.
CHARACTERIZATION OF METHYLATED VIM, 
TMEFF2 AND GDF15 AS A POTENTIAL SET 
OF EPIGENETIC MARKERS FOR BLADDER 
CANCER
O.S. Mankovska1–3, O.S. Skrypnikova2, 
G.V. Panasenko1, U.S. Slivka3, M.V. Vikarchuk4, 
O.A. Kononenko5, E.O. Stakhovskyy5, 
V.I. Kashuba1
1Institute of Molecular Biology and Genetics, 
NAS of Ukraine, Kyiv, Ukraine  
2National University of Kyiv-Mohyla Academy, Kyiv, 
Ukraine  
3ESC “Institute of Biology”, Taras Shevchenko  
National University of Kyiv, Kyiv, Ukraine  
4Institute of Urology, NAMS of Ukraine, Kyiv, Ukraine 
5National Cancer Institute, Kyiv, Ukraine
Bladder cancer is one of the most common cancers 
in Ukraine and in the world and a problem of its early 
diagnosis is still unresolved. The use of epigenetic 
markers, such as methylation of tumor suppressor 
genes, is a promising tool to assess the risks of the 
disease and its early detection. The aim of this study 
was to evaluate the potential of combination of tumor 
suppressor genes GDF15, TMEFF2, and VIM as diag­
nostic and differentiation markers for bladder cancer. 
The urine from patients with bladder (sample size 
is n = 42), renal (n = 13) and prostate cancers (n = 13) 
were collected, as well as from 5 healthy individuals 
as negative controls. DNA was precipitated by CTAB 
and isolated, using the standard phenol/chloroform/
isopropanol method. Methylation of VIM, TMEFF2, 
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and GDF15 promoters was detected by RealTime MSP 
PCR after the DNA bisulfite conversion. We found the 
presence of hypermethylation of at least one of 3 stu­
died genes in 69% of bladder cancer samples, while 
no methylation was detected in samples taken from 
healthy people. Among renal and prostate cancer 
samples VIM, TMEFF2 and GDF15 were not methylated 
in 11 from 13 samples and in 12 from 13 samples, re­
spectively. Conclusions: Our results are an evidence 
of possibility to use promoter methylation of GDF15, 
TMEFF2, and VIM to distinguish between bladder 
cancer and other uro­oncological diseases. The num­
ber of patients and healthy individuals should be in­
creased, to prove our preliminary results. 
CURRENT METHODS TO STUDY  
THE PROTEOME OF BREAST CANCER
M.G. Mazur, T.V. P’yatchanina
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine, Kyiv, 
Ukraine
According to epidemiological data, breast cancer 
(BC) — one of the most common cancers of the female 
population in the world. According to the National 
Cancer Registry (2014) 13 641 new cases of BC and 
5874 new cases of deaths due to this disease were 
registered in Ukraine. In the last decade, much atten­
tion is paid to the proteomic research as an integral 
part of the functional genomics of tumors. The most 
essential results of studies on the diagnostic features, 
action of therapeutic drugs, identification of predictive 
factors and tumor biomarkers are and will be intro­
duced in diagnostics and treatment in clinical practice. 
We reviewed the literature for the optimal technical 
solutions to perform the proteome research of breast 
cancer. Different types of mass spectrometry is used, 
especially the peptide­oriented Proteomics and me­
thods based on matrix. Using the described methods, 
the special groups of BC, associated with the mutated 
BRCA1 and BRCA2 were established, and also the bio­
markers for lobular and ductal carcinomas were cha­
racterized as well.  Protein expression patterns of three 
receptor negative breast cancers were compared with 
HER’s­2­positive tumors and more than 95% ER nega­
tive cases of BC with a poor prognosis were classified. 
Conclusions: MS technology plays a key role in the 
modern achievements of proteomics standards to im­
prove diagnosis, treatment and prognosis.
PROLIFERATION ACTIVITY AND EPITHELIAL-
MESENCHYMAL TRANSITION 
IN HEPATOCELLULAR CARCINOMA: A PILOT 
STUDY
D. Mezale, I. Strumfa, A. Vanags
Department of Pathology, Riga Stradins University, 
Riga, Latvia
Liver cancer is the fifth most frequently diagnosed 
cancer and the second leading oncologic death cause 
worldwide. The high mortality from hepatocellular carci­
noma (HCC) is mainly attributed to the invasion pattern 
and intrahepatic and/or extrahepatic meta stases, but 
the exact mechanism remains unclear. Yet, the escape 
of neoplastic cells from the solid tumor might be due 
to de­differentiation which occurs by loss of cell­to­cell 
contacts and the concomitant gain of migratory and 
invasive abilities. This phenotypical conversion of cells, 
collectively designated as epithelial­mesenchymal 
transition (EMT), has been described in different types 
of carcinoma including HCC. We aimed to evaluate the 
proliferation activi ty (by Ki­67) and EMT (by vimentin and 
E­cadherin) of hepatocellular carcinomas. In a retrospec­
tive study, 50 consecutive morphologically confirmed 
cases of HCC were enrolled. There were 36 (72.0%; 
58.2–82.6) males and 14 (28%; 17.4–41.8) females. The 
mean age was 63.8 ± 9.4 years (residual range 42–82). 
The expression of Ki­67, vimentin and  E­cadherin was 
detected by immunohistochemistry. The proliferation 
fraction was scored quantitatively (%) in the neoplastic 
nuclei. The mean proliferation fraction was 26.1 ± 18.2%. 
Expression of vimentin and E­cadherin was evaluated 
semi­quantitatively by intensity (scale, 0–3) and the 
fraction (%) of positive neoplastic cells. The mean 
expression of E­cadherin was 1.5 ± 1.0, comparable 
with the moderate intensity of peritumoral benign 
hepatocytes (1.7 ± 1.0) but being less than in reactive 
bile ducts (2.7 ± 0.4). HCCs were mostly negative (85.0% 
of cases) for vimentin. The hepatocytes were invariably 
negative while reactive bile ducts showed higher expression. 
Currently, there is a considerable body of literature indicating 
that hepatocellular EMT is a crucial event in HCC progres­
sion. However, expression of EMT marker vimentin was 
a rare event in the present group. Our data match with 
other studies, suggesting that HCC is a discohesive 
malignancy with low E­cadherin expression. Reduced 
E­cadherin expression correlates with lower overall sur­
vival for HCC patients, metastasis and vascular invasion. 
Conclusions: HCC is tumor with low proliferative activity 
indirectly indicates low efficacy of chemotherapy.
IS THE MRPS18-2 ONCOPROTEIN A MASTER 
REGULATOR OF CELL DIFFERENTIATION?
M. Mushtaq1, L. Kovalevska2, N. Iurchenko2, 
M. Mints3, L. Buchynska2, E. Kashuba1,2
1Department of Microbiology, Tumor and Cell 
Biology (MTC), Karolinska Institutet, Stockholm, 
Sweden  
2R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine, Kyiv, 
Ukraine  
3Department of Women’s and Children’s Health 
(KBH), Karolinska Institutet, Stockholm, Sweden
We have found that mitochondrial ribosomal 
protein S18­2 (MRPS18­2) is involved in regulation 
of the RB­dependent pathway. It binds to both, hypo­ 
and hyperphosphorylated RB protein. The binding 
between RB and S18­2 proteins is promoted when 
cytoplasmic S18­2 is targeted to the nucleus, and this 
disrupts the association of E2F1 with RB, as indicated 
by the increased level of free E2F1 in the nucleus. This 
presumably lifts the RB dependent block to S­phase 
entry in the cell cycle. We have also found that over­
Experimental Oncology 38, 128–140, 2016 (June) 137
expression of the human S18­2 immortalized primary 
rat embryonic fibroblasts and they showed properties 
of embryonic stem cells. Terminally differentiated skin 
fibroblasts were transformed upon S18­2 overex­
pression. Moreover, S18­2 increased in endometrial 
cancers compared with the normal endometrium and 
hyperplasia, based on a study of 42 patient biopsies. 
Elevated expression of S18­2 in stem and tumor cells 
(our findings and analysis of published microarray 
data) raises the question of whether this protein 
co­operates with the RB protein in differentiation 
and cancerogenesis. In the present work we aimed 
to chara cterize the pathways of cell fate regulation with 
the involvement of S18­2 and RB proteins. We showed 
that S18­2 protein, together with RB, plays a crucial 
role in cell dedifferentiation. We have found that over­
expression of S18­2 and RB is needed for maintenance 
of cell stemness. Such cells can differentiate into vari­
ous cell lineages under certain conditions. We have 
shown that S18­2 could enhance the telomerase 
activity. Overexpression of S18­2 induced chromo­
somal instability in the transfected cells. Conclusions: 
The 18­2 is a novel oncoprotein that also is involved 
in control on cell stemness.
ESR1 GENE POLYMORPHISMS IN PATIENTS 
WITH BENIGN DISORDERS OF THE FEMALE 
REPRODUCTIVE SYSTEM, IN DEPENDENCE 
ON CANCER HISTORY IN FAMILY
O.V. Paliychuk1, 2, Z.I. Rossoha3, L.Z. Polischuk1, 
V.F. Chekhun1
1R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine, Kyiv, 
Ukraine  
2Cherkassy Regional Oncology Center, Cherkassy, 
Ukraine  
3Reference Center for Molecular Genetic Studies 
of NAMS of Ukraine, Kyiv, Ukraine 
It is not known how the single nucleotide polymorphism 
(SNP) of the estrogen receptor gene (ESR1) is associated 
with benign disorders of the female reproductive system 
(FRS). Such studies are badly needed for women with on­
cogenetic syndromes, when tumors of FRS are inherited. 
We wanted to interview patients with benign pathology 
of FRS from families with a family cancer syndrome and 
also to determine the frequency of polymorphisms, such 
as T397C and A351G in ESR1. We analyzed the question­
naires of the medical genetic counseling and isolated 
genomic DNA of peripheral blood of 120 women (aged 
23 to 83 years), including 65 with benign pathology of FRS 
(uterine, ovarian, breast). In the families there was the 
cancer syndrome (Lynch II). The 55 healthy women aged 
19–78 years were analyzed similarly; there was no ag­
gregation of malignant tumor dise ases in pedigree. The 
results of a comprehensive clinical and clinico­genealog­
ical research have shown that in families of 65 probands 
with benign patho logy of FRS, there were malignancies 
mostly of FRS (cancer of ovary, breast, endometrium), 
and also of gastrointestinal tract (colon and gastric can­
cer) and others, that corresponds to the Lynch syndrome 
type II. In families of probands with benign disorders of the 
breast, uterus, and ovary from families were cancer of RFS 
were detected, we have found an aggregation of malignant 
tumors of the type of family cancer syndrome and also 
significant changes in the frequency of T397C polymor­
phisms, while no changes in the frequency of A351G poly­
morphism. Statistical calculations showed that in terms 
of odds ratio the risk of benign pathology of FRS is the 
largest by bi­allelic SNP of the ESR1 gene (T397C) and 
this risk is 5.2 at 95% confidence interval (1.42–19.06). 
Conclusions: Our results can be used to create the ge­
netic risk groups to develop benign tumors in women from 
families with a family cancer syndrome.
RELATIONSHIP BETWEEN LEVELS 
OF COPPER- AND IRON-CONTAINING 
PROTEINS AND CLINICAL 
AND PATHOLOGICAL FEATURES OF BREAST 
CANCER 
A.O. Pavlova, N.Yu. Lukianova, V.F. Chekhun
R.E. Kavetsky Institute of Experimental  
Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine
Breast cancer (BC) is one of the most common 
forms of cancer diseases in many countries. The 
problem is not only that the BC in often asymptomatic 
at the early stages, but also in the absence of reliable 
markers for predicting its course. According to the 
literature, copper­ and iron­containing proteins might 
be considered as potential markers of prognosis of ma­
lignant progression and also the promising target for 
anticancer therapy. We have examined the relationship 
of ceruloplasmin (CP) and transferrin (TF) in serum 
and tumor tissue of BC patients with their clinical and 
pathological characteristics, including molecular sub­
type. We studied the 276 BC patients at the stage I–III 
and of age 23–89 years (average age was 55.4 ± 7.3). 
In 58.7% of patients with BC the CP level in serum was 
significantly higher than in relatively healthy women, 
and the TF level was below the performance standards 
in 62.3% of patients. Also we have found that CP levels 
correlate directly with the stage of disease and the 
development of metastases in regional lymph nodes. 
Noteworthy, the TF levels in the blood serum were 
dependent on the histological tumor types. We found 
that high TF levels observed frequently in the serum 
of patients with stage I BC (r = −0.28) and luminal 
subtype A tumors (r = 0.45). The lowest level of TF was 
observed in patients with luminal subtype B tumors 
and in basal cancers (r = 0.35). Increased expression 
of TF was more characteristic for BC patients with a low 
degree of differentiation (r = −0.39), this correlated 
with the presence of metastatic lymph nodes (r = 0.48). 
The largest number of CP positive tumors (80%) was 
observed in the group of Her2/neu positive cancers. 
Conclusions: Our data on the relationship between 
levels of CP and TF and the clinical and pathological 
parameters and molecular subtypes is a promising line 
for the further research, and may be used as additional 
prognostic markers of the course of tumor disease.
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ABILITY OF QUERCETIN TO CORRECT 
THE PARANEOPLASTIC HEMATOLOGICAL 
SYNDROME
О.М. Piaskovska1, Yu. Jakshibaeva1, G. Gorbik1, 
V.G. Vedmid’2, A.S. Shalamaj2, G.I. Soljanik1
1R.E. Kavetsky Institute of Experimental  
Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine  
2PJSC SIC “Borshchahivskiy Chemical  
Pharmaceutical Plant”, Kyiv, Ukraine
It is known that a malignant tumor is able to cause 
the development of paraneoplastic syndrome (PNS). 
Among the various manifestations of PNS a special 
place is taken by hematology. The use of drugs for 
therapeutic correction of PNS is limited due to their 
toxicity and the risk of stimulating cancer. We wanted 
to investigate the ability of quercetin to counteract 
the hematologic manifestations of PNS, induced 
by tumor growth. The C57BL mice with the Lewis lung 
carcinoma (LLC/R9) were used as a model. Treatment 
with quercetin started the day after inoculation of LLC/
R9 cells into mice. Growth of LLC/R9 cells in mice 
was accompanied by pronounced signs of tumor­
associated thrombocytopenia and anemia. Quercetin 
had no influence on red blood cells. However, the 
bone marrow cells were increased in number. Quer­
cetin treatment resulted in increase of the number 
of platelets up to 52% (p < 0.05), particularly when 
a dose of 0.45 g/kg was used, compared to the con­
trol animals. Moreover, we have found increase in the 
total number of myelokaryocytes (1.7 fold, p < 0.05) 
and megakaryocytes (2.6 fold, p < 0.05). Noteworthy, 
the fraction of oxyphilic megakaryocytes was larger. 
Quercetin treatment has not stimulated tumor growth 
or metastasizing. Conclusions: The fact that quercetin 
can diminish the tumor­associated thrombocytopenia 
without stimulating tumor growth and metastasizing, 
makes it a putative drug for the support of therapy for 
cancer patients.
PROSTATE TUMORS CHARACTERIZATION 
BY Notl-MICROARRAYS
E.E. Rosenberg1, G.V. Gerashchenko1, 
V.V. Gordiuyk1, Yu.N. Bondarenko2, 
R.O. Danilets2, V.I. Kashuba1
1Institute of Molecular Biology and Genetics, 
NAS of Ukraine, Kyiv, Ukraine  
2Institute of Urology, NAMS of Ukraine, Kyiv, Ukraine
Prostate cancer is the second most common cancer 
type among men worldwide. Most of malignant pros­
tate tumors are dormant and don’t need any surgery. 
Some percent of them would progress into aggressive 
metastatic type. Mechanisms of this transition are still 
being elucidated. A number of regions in the short arm 
of human chromosome 3 were found to be frequently 
deleted or methylated in cancer genomes. We aimed 
to characterize different types of prostate tumors 
by chromosome 3 specific NotI­microarray to find the 
changes and putative biomarkers. NotI­microarray 
microarray with 180 genomic loci (clones) associated 
with chromosome 3 was used to detect genetic and 
epigenetic changes in 15 prostate adenomas and 
14 prostate carcinomas. Pool from 4 prostate inflam­
mation samples was used as a reference. NotI­micro­
array results were verified for selected genes (FGF12, 
GATA2, LMCD1, and TESSP2 as control) by bisulfite 
sequencing. Alterations in 158 NotI­clones (genes/
loci) were found. There were observed 1624 cases 
of deletion/methylation and 24 cases of amplifica­
tion/demethylation. Genes with high percent of dele­
tion/methylation (> 30%) could be divided into three 
groups: 1) previously not shown to be associated 
with carcinogenesis; 2) known to be involved in non­
prostate cancer; 3) previously shown to be associated 
with prostate cancer. Some of these genes have sig­
nificant differences in deletion/methylation frequency 
in different prostate tumors: 1) high Gleason score 
carcinoma vs adenomas and low, medium Gleason 
score carcinomas — 9 genes: LOC440944/SETD5, 
OSBPL10/ZNF860, CLCN2, FAM19A4, PRSS42/MYL3, 
VHL, BBX, LMCD1, CMTM6 (p < 0.001); 2) prostate 
ade noma vs carcinoma – 6 genes: CAND2, GATA2, 
FAM19A4, KY, ALDH1L1, MAP4 (p < 0.05). Methyla­
tion of NotI­site was found in 40–80% of clones for 
FGF12 gene, 30–70% — for GATA2 and LMCD1 genes, 
and <10% — for TESSP2 gene. Bisulfite sequencing 
proved NotI­microarray results. Conclusions: Most 
common changes of chromosome 3 in prostate tumors 
are deletion and/or methylation. We found 9 genes 
with significant differences in deletion/methylation fre­
quencies between carcinomas of high Gleason score 
compared with adenomas and low/medium Gleason 
score carcinomas; and also 6 genes when prostate 
adenomas were compared with all carcinomas. NotI­
microarray is a powerful tool for screening of genetic 
and epigenetic alterations in prostate cancer.
DEPENDENCE OF EFFICIENCY 
OF ANTICLASTOGENIC ACTIVITY OF SODIUM 
HUMATE IN RADIATION-INDUCED 
MUTAGENESIS IN PATIENTS WITH THYROID 
CANCER
V.N. Shkarupa
National Research Center for Radiation  
Medicine, NAMS of Ukraine, Kyiv, Ukraine
Determining the molecular basis of antimutagenes 
and anticlatogenes is important not only to prevent, but 
also to inhibitcarcinogenesis at the different stages. 
The XPD and XRCC1 genes are important regula­
tors of DNA repair systems. Upon ionizing radiation 
and action of alkylating agents polymorphisms, such 
as Lys751Gln in XPD and Arg399Gln in XRCC1 are 
markers for the patient survival after chemotherapy 
and also of sensitivity to a range of cytotoxic drugs. 
We wanted to evaluate anticlastogenic efficiency 
of the sodium humate (10 mg/ml) after γ­irradiation 
(137Cs) at a dose of 1 Gy in the culture of peripheral 
blood lymphocytes of patients with thyroid cancer, 
depending on polymorphisms Lys751Gln in XPD and 
Arg399Gln  in XRCC1. In all studied cases, when ho­
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mozygous polymorphism was observed for any of the 
abovementioned genes, the antimutagenic effect 
of sodium humate was absent or reduced significantly. 
However, the risk of antimutagenic reduction was not 
statistically significant, due to the low specificity (0.33) 
of the marker at simultaneous high sensitivity (1.00). 
This suggests that polymorphisms Lys751Gln in XPD 
and Arg399Gln in XRCC1 are not the specific mar­
kers of radioprotective efficiency of antimutagenes. 
Reduction of antimutagenic effectiveness of sodium 
humate in lymphocytes culture in patients with thy­
roid cancer may be due to inhibition of the functional 
activity of other genes. Conclusion: Our results are 
prerequisites for development of new approaches 
for correcting etiopathogenetical mechanisms that 
are related to inhibition of protective processes upon 
cancerogenesis.
CARBOSILANE-VIOLOGEN-PHOSPHORUS 
DENDRIMERS AS POTENTIAL 
NANOCARRIERS OF ANTI-APOPTOTIC 
siRNAs IN CANCER THERAPY
A. Szwed, K. Milowska, M. Ionov, 
M. Bryszewska, T. Gabryelak
Department of General Biophysics, Faculty 
of Biology and Environmental Protection, University 
of Lodz, Lodz, Poland
Apoptosis, namely programmed cell death, have 
a crucial role in development, as well as in maintenance 
of the tissues. The uncontrolled propagation and loss 
of the ability to undergo apoptosis of the normal cells 
lead to transformation into cancer cells. The major 
regulators of the apoptotic process are the Bcl­2 family 
proteins. Among the group of the apoptosis inhibitors 
are Bcl­2, Bcl­xl, and Mcl­2. One of the mechanisms 
of the suppression of synthesis of anti­apoptotic pro­
teins is a process of selective gene silencing by small 
interference RNAs (siRNAs). This study examines 
a perspective of using of two generation of carbosi­
lane­viologen­phosphorus dendrimers as effective 
and safe carriers of anti­apoptotic siRNAs (siBcl­xL, 
siBcl­2, siMcl­1) for cancer therapy. The complexes 
were characterized, using fluorescence quenching, 
circular dichroism and gel electrophoresis methods. 
The proliferation of HL­60 (human promyelocytic leu­
kemia) cells in result of interaction with dendriplexes 
was evaluated by MTT cytotoxicity assay. The results 
have shown that formation of complexes occurs 
between all of anticancer siRNAs and carbosilane­
viologen­phosphorus dendrimers of both generations. 
However, the complexes have been formed at diffe­
rent dendrimer/siRNA molar ratio. The cytotoxicity 
assay has shown that mixture of all 3 siRNAs is more 
effective than single siRNA. In case of single siRNAs 
only Bcl­xl complexed with 1st generation dendrimer 
caused statistically significant decrease in HL­60 cell 
viability. Conclusions: Combination of few siRNA 
on carbosilane­viologen­phosphorus dendrimers 
is a promising way to induce apoptosis in tumor cells. 
EFFECT OF MELANIN, THE AGONIST 
OF PPARγ RECEPTOR ON THE MUCOUS 
MEMBRANE OF THE COLON CANCERS
O.K. Voronina, T.V. Beregova, M.E. Dzerzhinskyj
ESC “Institute of Biology”, Taras Shevchenko 
National University of Kyiv, Kyiv, Ukraine
It is known that one of the factors in the deve­
lopment of colon cancers is long hypergastrinemia 
that is caused by low levels of HCl in the stomach. The 
appearance of undifferentiated cells and their pro­
liferation is observed prior malignant transformation 
of cells of the intestinal mucosa. Therefore, one of the 
possible ways of preventing the emergence of tumors 
is the effect on PPARγ receptors as central regulators 
of cell differentiation, apoptosis and inflammatory 
reactions. In the recent years, more attention is drawn 
to natural compounds, among which there is the natu­
ral agonist of PPARγ receptor melanin, which has low 
toxicity. Research conducted at 5­month­old male rats 
in 3 groups: 1 — control; 2 — omeprazole (14.0 mg/kg) 
was administered for 28 days; 3 — melanin (0.1 mg/
kg) and omeprazole were administered for 28 days. 
Paraffin sections of the colon (removed and fixed) were 
stained with anti­p53 antibodies (Dako, Denmark) and 
Mayer’s hematoxylin. We have found that the colon 
mucosa of rats in the control group corresponded 
to normal. In the intestinal mucosa of rats in group 2 the 
deepening intestinal crypts with significant destruction 
of the epithelial layer was seen. Also, white blood cells 
were located throughout the mucosal surface, as ob­
served at mucous membrane inflammation. Expres­
sion of p53 protein in epitheliocytes was significantly 
increased compared with the control group. 28­day 
concomitant administration of omeprazole and melanin 
prevented the development of changes in the lining 
of the large intestine of rats in 3rd group: no gland atro­
phy or undifferentiated cells were observed. Expression 
of p53 protein in epitheliocytes was weak, which allows 
to conclude that the significant slowdown dysplastic 
changes in the mucosa took place. Conclusions: The 
introduction of melanin against long hypergastrinemia 
significantly decreased the carcinogenesis, inhibiting 
proliferation and degeneration of atypical epithelial cells 
in the lining of the stomach.
REDOX MECHANISMS OF ANTITUMOR AND 
ANTIMETASTATIC ACTION OF L-ARGININE 
HYDROCHLORIDE AND COENZYME Q10
A.V. Vovk1, A.P. Burlaka1, I.I. Ganusevich1, 
V.V. Golotyuk2, S.M. Lukin1
1R.E. Kavetsky Institute of Experimental  
Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine  
2Ivano-Frankivsk National Medical University,  
Ivano-Frankivsk, Ukraine
One of approaches to find the innovative anticancer 
drugs is the use of compounds — donors of nitric oxide 
(NO) and molecules that control the speed of electron 
transport in mitochondria, such as coenzyme Q10 (CoQ10). 
We wanted to investigate the redox­dependent mecha­
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nism of antitumor and antimetastatic action of L­arginine 
hydrochloride ( L­Arg) and SoQ10 in vivo. The study was 
conducted on the S57Vl mice with the introduced Lewis 
lung carcinoma. The drugs were injected intraperitoneally 
at high and low doses, i.e. L­Arg (60 and 360 mg/kg body 
weight of the animal), CoQ10 (0.2 and 1.2 mg/kg of the 
animal), and L­Arg with CoQ10 together. The L­Arg in high 
doses caused inhibition of tumor growth for 48.0 ± 8.0%, 
metastasizing was decreased, gene ration of O2 and 
NO levels in the tumor rise to the values of 1.23 ± 0.14 and 
2.26 ± 0.31 nM/mg·min, the matrix metalloproteinases 
(MMP)­2 and ­9 acti vity diminished to 3.55 ± 0.80 and 
4.8 ± 1.0 relative units, respectively (p < 0.05). The L­Arg 
in low doses stimulated tumor growth, metastasizing 
and the level of active forms of MMP­2 and ­9 were 
increased to the 8.44 ± 2.7 and 9.8 ± 3.1 relative units, 
respectively (p < 0.05). The CoQ10 in high doses reduced 
the rate of generation of O2· to 0.44 ± 0.09 nM/mg·min 
and NO (p < 0.05) significantly. Tumor growth was inhi­
bited by 54.0 ± 11.3%. The combined use of L­Arg and 
CoQ10 in high doses caused inhibition of tumor growth 
by 51.0 ± 7.4%. Conclusions: The low doses of L­Arg 
positively modulates the MMPs activity that contribu­
tes to the progression of tumors. The use of L­Arg and 
CoQ10 led to such redox state of the tumor, which is char­
acterized by decreased activity of MMP­2 and ­9 and, 
therefore, contributes to inhibition of tumor invasion and 
metastasis.
ROLE OF HEPCIDIN IN THE FORMATION 
OF A DEGREE OF MALIGNANCY OF BREAST 
CANCER
T.N. Yalovenko, N.Yu. Lukianova, V.F. Chekhun
R.E. Kavetsky Institute of Experimental  
Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv, Ukraine
Despite the development of the new approaches 
of diagnostics and treatment, treatment outcomes 
of breast cancer (BC) patients often remain unsatisfac­
tory. The reason for this is genetic and morphological 
heterogeneity of tumors, which usually is assessed 
by the degree of malignancy. The lack of clear criteria 
for determining the degree of malignancy dictates 
the need to find additional markers associated with 
an aggressive course of BC. We wanted to monitor the 
role of hepcidin part in shaping the degree of malig­
nancy. To do so, we used cell lines in vitro and clinical 
materials ex vivo. 4 BC cell lines of different degrees 
of malignancy (T47D, MCF­7, MDA­MB­231, MDA­
MB­468) and ex vivo clinical material of 110 BC patients 
of the stages I–II were used. The degree of malig­
nancy of cells was evaluated by the following criteria: 
receptor status, proliferation activity, adhesive and 
invasive properties. We have found that hepcidin was 
expressed differently in the cells lines. The highest 
expression was observed in cell lines, characterized 
by a high degree of malignancy, MDA­MB­231 and 
MDA­MB­468. Expression of hepcidin directly corre­
lated with proliferative indices (r = 0.45) and invasive 
cell activity (r = 0.51), content of “free” iron (r = 0.43); 
and inversely correlated with the presence of estrogen 
(r = −0.39) and progesterone (r = −0.41) receptors. 
In clinical material hepcidin expression correlated with 
cell proliferative activity (r = 0.38) and their receptor 
status (r = −0.33). At the same time hepcidin levels 
correlated with the stage of the disease (r = 0.27), 
the development of regional metastases in the lymph 
nodes (r = 0.41) and a low degree of tumor (r = 0.32). 
The overall survival of BC patients is significantly worse 
when hepcidin was expressed, at the background 
of no estrogen receptor and high proliferative activity 
of tumor cells. Conclusions: Our data suggest that 
hepcidin expression levels in tumor cells may be used 
as an additional criterion for prediction of clinical 
course of BC.
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